Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials

Table 3 Patients and procedural characteristics of included trials

Study	Mean age (years)	Male (%)	Baseline LVEF (%) (mean ± SD)	Time from PCI to MSC therapy (days)	Cell resource	Mean cell dose	Delivery method
Chen et al. 2004 [7]	58	95.7	41.85 ± 8.3	18.3	BM	4.8–6 × 10^10b	IC
Chullikana et al. 2015 [10]	48	90.0	43.25 ± 4.01	2	BM	2 × 10⁶	IV
Gao et al. 2013 [28]	57	93.0	50.71 ± 1.5	17.1	BM	3.08 × 10⁶	IC
Gao et al. 2015 [27]	57	94.6	51.51 ± 0.95	6.2	Umbilical cord	6 × 10⁶	IC
Hare et al. 2009 [29]	58	71.7	49.81 ± 10.25	<7	BM	80 × 10⁶	IV
Houtgraaf et al. 2012 [12]	59	78.6	45.36 ± 2.73	<1	Adipose tissue	1.74 × 10⁶	IC
Lee et al. 2014 [30]	54	75.4	49.57 ± 8.63	25	BM	72 × 10⁶	IC
Wang et al. 2014 [31]	57	60.3	28.70 ± 4.33^a	15	BM	100 × 10^6b	IC

^aHighlights a considerable low baseline LVEF; ^bhighlights a significantly higher number of cells
BM bone marrow, IC intracoronary, IV intravascular, LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention, SD standard deviation,

ISSN: 1757-6512